Abstract 1398
Background
Eribulin is approved for treatment of advanced/metastatic breast cancer and previously treated, unresected liposarcoma. E7389-LF is a liposomal formulation of eribulin. The maximum tolerated dose (MTD) in a prior phase 1 study was 1.4 mg/m2 Q3W or 1.5 mg/m2 Q2W.
Methods
The primary objective was to determine MTD and compare the tolerability of higher (> prior) Q3W doses vs the prior Q2W dose. E7389-LF was administered (3 + 3 design) intravenously Q3W (day 1 of a 21-day cycle) and Q2W (days 1 and 15 of a 28-day cycle) to solid tumor pts in Japan for which no alternative standard or effective therapy exists. Planned dose ranges were 1.0-2.5 mg/m2 Q3W and 1.0-1.5 mg/m2 Q2W.
Results
21 pts were enrolled; 3, 3 and 6 pts in 1.0, 1.5 and 2.0 mg/m2 Q3W; 3 and 6 pts in 1.0 and 1.5 mg/m2 Q2W, respectively. 10 pts were male, median age was 58 years (range, 22-68), and 11 had ECOG-PS 0. One dose-limiting toxicity was observed in the 2.0 mg/m2 Q3W group (febrile neutropenia; n = 6); thus, 2.5 mg/m2 Q3W was not assessed. Adverse events ≥ grade 3 included neutropenia (67%), leukopenia (48%), anemia (19%), increased ɣ-glutamyltransferase, lymphopenia, and thrombocytopenia (each 14%). The MTDs were 2.0 mg/m2 Q3W and 1.5 mg/m2 Q2W. Partial response was noted in 4 pts (19%) with esophageal squamous cell carcinoma, adenoid cystic carcinoma, urothelial cancer, and small cell carcinoma of the cervix. Area-under-the-curve (AUC) values of total eribulin were higher and AUC of unbound eribulin in plasma lower with E7389-LF vs the standard dose of eribulin (Table).Table:
348P
Eribulin formulation/dose | Plasma AUC (h*ng/mL) of eribulin | |
---|---|---|
Total | Unbound | |
E7389-LF 1.0 mg/m2 | 26300 | 98.1 |
E7389-LF 1.5 mg/m2 | 34700 | 120 |
E7389-LF 2.0 mg/m2 | 39100 | 148 |
Standard eribulin 1.4 mg/m2 | 673 | 336 |
Conclusions
E7389-LF was well tolerated in Japanese pts with advanced solid tumors with antitumor effects in several tumor types. Plasma AUC of eribulin after administration of E7389-LF suggested a promising exposure profile of the liposomal formulation in humans. The 2.0 mg/m2 Q3W regimen was recommended for further investigation in an expansion cohort of specific tumor types.
Clinical trial identification
NCT03207672.
Editorial acknowledgement
Legal entity responsible for the study
Eisai Co., Ltd.
Funding
Eisai Co., Ltd.
Disclosure
N. Yamamoto: Research grant / Funding (institution): Chugai, Taiho, Eisai, Lilly, Quintiles, Astellas, BMS, Novartis, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, Kyowa-Hakko Kirin, ONO Pharmaceutical Co. LTD, Takeda, Janssen Pharma, MSD, Merck; Honoraria (self): ONO Pharmaceutical Co. LTD, Chugai, AstraZeneca, Pfizer, Lilly, BMS; Advisory / Consultancy: Eisai, Otsuka, Takeda, Boehringer Ingelheim, Cimic. S. Iwasa: Research grant / Funding (institution), grants from Eisai, during the conduct of the study: Eisai, Eli Lilly, Chugai, Novartis, Merck-Serono, Daiichi-Sankyo, Bristol-Myers Squibb, Bayer; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly, Taiho, Chugai, ONO Pharmaceutical Co., LTD. A. Shimomura: Travel / Accommodation / Expenses, personal fees: Chugai; Travel / Accommodation / Expenses, personal fees: Novartis; Travel / Accommodation / Expenses, personal fees: Pfizer; Travel / Accommodation / Expenses, personal fees: Nippon Kayaku; Travel / Accommodation / Expenses, personal fees: AstraZeneca; Travel / Accommodation / Expenses, personal fees: Eisai. S. Kondo: Research grant / Funding (institution): ASLAN Pharmaceuticals; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Pfizer. K. Yonemori: Research grant / Funding (self), trail management at site: Eisai; Honoraria (self): Eisai. Y. Fujiwara: Research grant / Funding (institution): Abbvie, AstraZeneca, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Incyte, Merck Serono, Novartis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Taiho, Sysmex, ONO, Novartis, MSD, Chugai, BMS, AstraZeneca; Advisory / Consultancy: MSD, ONO, AstraZeneca, BMS. T. Shimizu: Research grant / Funding (institution): Novartis, Eli Lilly, Bristol-Myers Squibb, Daiichi-Sankyo, Millenium-Takeda, AbbVie, AstraZeneca, Eisai, PharmaMar, 3D-Medicine, Symbio Pharmaceuticals, Chordia Therapeutics, Five Prime; Advisory / Consultancy: The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR) Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong. All other authors have declared no conflicts of interest.
Resources from the same session
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract
3353 - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Presenter: Jalid Sehouli
Session: Poster Display session 2
Resources:
Abstract